摘要
目的 观察前列腺素E1治疗难治性心力衰竭的临床疗效。方法 难治性心力衰竭患者 84例 ,随机分为两组 :(1)前列腺素E1治疗组 :4 2例 ;(2 )酚妥拉明对照组 :4 0例。在综合治疗的基础上 ,治疗组加用前列腺素E110 0～ 2 0 0 μg +5 %葡萄糖 2 5 0～ 5 0 0ml,静脉点滴 ,每天 1次 ;对照组加用酚妥拉明 10～ 2 0mg +5 %葡萄糖 2 5 0ml,静脉点滴 ,每天 1次 ,两组疗程均为 14d。结果 治疗组总有效率为 92 .9% (39/ 4 2 ) ,对照组总有效率为 77.5 %(31/ 4 0 ) ,两组相比较 ,有显著性差异 (P <0 .0 5 )。LVDd :治疗组与对照组相比较 ,有显著性差异 (P <0 .0 5 )。LVEF治疗组与对照组相比较有显著性差异 (P <0 .0 5 )。结论 前列腺素E1治疗难治性心力衰竭效果显著 ,副作用少 ,具有良好的临床应用前景。
Objective To observe the clinical effectiveness of prostaglandin E1 for the treatment of refractory heart failure.Methods Eighty four patients who were corresponded to the standard of refractory heart failure were randomly allocated into the treatment group of prostaylandin E1( 42 cases)and the control group of phentolamine( 40 cases).On the basis of being given digitalis and diurelics,the treatment group were given additional 250～500 ml of glucose solution plus prostaglandinE1 100～200 μg,qd. The control group were given additional 250 ml of glucose solution plus Phentolamine 10～20 mg,qd, with 14 days as a treatment course.Results The effective rate was 92.9% in the treatment group, while was 77.5% in the control group with a significant difference( P <0.05).There was a significant difference of LVDd between treatment group and control group.There was also a significant difference of LVEF between treatment group and control group.Conclusion Prostaglandin E1 possesses obvious effect for the treatment of refractory heart failure.
出处
《江西医学院学报》
2003年第3期52-54,共3页
Acta Academiae Medicinae Jiangxi
